Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Phase II trial of vorinostat in advanced melanoma.

Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A.

Invest New Drugs. 2014 Jun;32(3):526-34. doi: 10.1007/s10637-014-0066-9. Epub 2014 Jan 25.

PMID:
24464266
2.

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.

Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH.

Nat Rev Drug Discov. 2010 Nov;9(11):843-56. doi: 10.1038/nrd3216. Epub 2010 Oct 29. Review.

PMID:
21031001
3.

State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003.

Zelent A, Waxman S, Carducci M, Wright J, Zweibel J, Gore SD.

Clin Cancer Res. 2004 Jul 15;10(14):4622-9.

4.

Clinical trials referral resource. Clinical trials with perillyl alcohol.

Zweibel J, Ho P, Sepelak SB, Saunders J, Cheson BD, Nelson A.

Oncology (Williston Park). 1997 Dec;11(12):1817, 1820. No abstract available.

PMID:
9436188
5.

Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.

Ellis MJ, Leav BA, Yang Z, Rasmussen A, Pearce A, Zweibel JA, Lippman ME, Cullen KJ.

Mol Endocrinol. 1996 Mar;10(3):286-97.

PMID:
8833657

Supplemental Content

Loading ...
Support Center